Document

aaaa

Pages

01 | 02
Search

 


Page 01

SUBJECT: MALARIA CHEMOPROPHYLAXIS  AND MENINGCLCOCCAL VACINATION)

UNCLASSIFIED


ROUTINE





RATUZYUW RHDJGAAIOO9  2890034-UUUU--RHDIXMP.
ZNR UUUUU
R 101528Z OCT 90
FM NGB ANDREWS AFB MD//SGPi/
TO AIG 7301//CC//SG//
AIG  7311//CC//SG//
RUCIRMA/109AEF MINNEAPOLIS ST PAUL IAP MN//CC//
RUVRBMA/118AES  NASHVILLE  IAP  TN//SG//
RUVOBJA/137AEF WILL ROGERS WORLD APRT OKLAHOMA CITY
       OK//SG/SGNI//
RUVABIA/139AEF  STRATTON ANGA NY//DOCM//
RUVABOA/142AEF  MCCA NEW CASTLE DE//DOCM//
RUWFPAA/146AES  CHANNEL ISLANDS ANGB CA//SGA//
RUVRBIA/156AEF  CHARLOTTE DOUGLAS IAP NC//CC//
RUVRBPA/167AEF  EWVRA SHEPPAAD FLD MARTINSBURG  WV//SGO//
RUVRBGA/183AEF  ALLEN C THOMPSON FLD MS//SG//
RUVHBKA/ 187AEF CHEYENNE MUNI APRT WY//SGO//
ZEN 113TFW ANDREWS AFB MD//SG//
ZEN NGB  ANDREWS  AFB MD//SGAX//SGAT//
BT
UNCLAS
QQQQ

SUBJECT: MALARIA CHEMOPROPHYLAXIS  AND MENINGCLCOCCAL VACINATION)
GUIDELINES FOR OPERATION DESERT SHIELD REFERENCES:  DA WASHINGTON
DC//SGPS-PSP-D MSG, 3117OOZ AUG 90.  SAME SUBJECT.
B.  HQ USAF/SGP LTR, 6 NOV 89.  AIR FORCE GUIDELINES FOR MALARIA
PROPHYLAXIS.
C.  HO USAF BOLLING AFB DC//SGPA MSG 072000Z SEP 90, SAME SUBJECT.
1.  MALARIA CHEMOPROPHYLAXIS INFORMATION PROVIDED BY THE ARMED FORCES
MEDICAL INTELLIGENCE CENTER  (AFMIC) AND OTHER SOURCES INDICATE THE
FOLLOWING NOTE THAT THIS IS A CHANGE  IN  ANG  POLICY:
A. NOT ALL INDIVIDUALS OR UNITS DEPLOYED FOR OPERATION DESERT SHIELD
NEED TO BE STARTED ON MALARIA PROPHYLAXIS.
B. NO CURRENT MALARIA TRANSMISSION HAS  BEEN  IDENTIFIED  IN  EASTERN
SAUDI ARABIA, BAHRAIN, JORDAN, KUWAIT, QATAR, OR THE UNITED ARAB
EMIRATES.  RIYADH, JEODAH, AND DHAHRAN ARE CONSIDERED RISK FREE.
--- INDIVIDUALS DEPLOYING TO THESE AREAS ARE NOT REQUIRED TO CONSUME
MALARIA PROPHYLAXIS--- HOWEVER, A MINIMUM OF A SIX-WEEK SUPPLY  (6
TABLETS) OF CHLOROQUINE PHOSPHATE TABLETS  QNSN: 6505-00-117-6450), OR
DOXYCYCLINE SHOULD BE ISSUED TO ALL INDIVIDUALS SINCE FUTURE
OPERATIONS MAY INCLUDE TRAVEL TO  MALARIA  AREAS.
C. INDIVIDUALS DEPLOYING TO UNKNOWN SITES, OR WITH  A  HIGH  RISK  OF
DIVERTING, OR DEPLOYING THROUGH, AREAS OF KNOWN MALARIA RISK SHOULD
BE STARTED ON  CHLOROQUINE  PROPHYLAXIS.
D. IN SAUDI ARABIA, MALARIA TRANSMISSION OCCURS YEAR ROUND BUT IS
LIMITED-TO THE WESTERN PROVINCES, WITH THE MAIN THREAT IN THE
SOUTHWEST.  LIMITED MALARIA TRANSMISSION OCCURS IN EGYPT,  IRAQ,
TURKEY, AND OMAN.  TRANSMISSION IS WIDESPREAD IN NORTH YEMEN, SOUTH
YEMEN, AND  IRAN.
E. SUMMARY GUIDELINES FOR MALARIA PROPHYLAXIS:
;I) ALL SHOULD BE ISSUED DOXYCYCLINE OR CHLOROQUINE.
;2) INDIVIDUALS GOING TO HAZARDOUS OR UNKNOWN AREAS SHOULD TAKE THEIR
MALARIA PROPHYLAXIS  (A OR B BELOW): -
A) DOXYCYCLINE (DOXYCYCLINE 100 MG  PO  QD  BEGINING  3
DAYS PRIOR, DURING, AND FOR 28 DAYS AFTER  TRAVEL  TO  A MALARIA HAZARD
AREA).  DOXYCYCLINE IS PREFERRED DUE  TO  ADDED  COVERAGE OF MANY OTHER
PATHOGENS CAUSING DIARREHA.  THIS IS THE RECOMMENDED MALARIA
POPHYLAXIS FOR FLYING PERSONELL, AND MAY BE CONSIDERED FOR USE EVEN


                                         UNCLASSIFIED                                     

[Top]


Page 02

ROUTINE                                   UNCLASSIFIED


PAGE 02 OF 02    RHDJGAA 1009                       003888     16/0049Z
IN LOW MALARIA THREAT AREAS.
;B) CHLOROQUINE PHOSPHATE 500 MG (300 MG BASE) (ONE BY  MOUTH  EACH
WEEK STARTED TWO WEEKS PRIOR TO EXPOSURE, CONTINUED WEEKLY DURING
EXPOSURE, AND FOR SIX-TO-EIGHT WEEKS POST EXPOSURE).  CHLOROQUINE
RESISTANT MALARIA IS NOT A PROBLEM IN POTENTIAL OPERATIONAL AREAS.
;3) IF NO MALARIA HAZARD AREA WAS ENTERED, INDIVIDUAL SHOULD RETURN
THEIR MALARIA PROPHYLAXIS TO THE ISSUER.
THE MEDICAL PERSONNEL IN THE AOR WILL BE THE AUTHORITY FOR
DESIGNATING A MALARIA HAZARD AREA AND MAY AUTHORIZE INDIVIDUALS  TO
STOP (OR START) TAKING MALARIA PROPHYLAXIS.
(4) IF MALARIA HAZARD AREA WAS ENTERED, THEN NORMAL TERMINAL
PROPHYLAXIS OF EIGHT, WEEKLY DOSES OF 45 MG PRIMAOUINE SHOULD BE
ISSUED, IN ADDITION TO CONTINUING DOXYCYCLINE OR CHLOROQUINE,
FOLLOWING RETURN TO CONUS.  (OVALE AND/OR VIVAX-MALARIA  ARE  PRESENT
IN AOR MALARIA AREAS).
2. MENINGOCOCCAL IMMUNIZATION (QUADRAVALENT, A/C/Y/WI35, NSN 6505 01
2865312) SHOULD BE BROADENED TO INCLUDE ALL DEPLOYING PERSONNEL  AS
SUPPLIES ALLOW.  LACK OF MENINGOCOCCAL IMMUNIZATION WITHIN 5 YEARS
SHOULD NOT BE CONSIDERED A DETRIMENT TO DEPLOYMENT OF NONMEDICAL
PERSONNEL.
3. POINT OF CONTACT IS MAJ PHILIP A. LA KIEN, NGB/SGP DSN 858-8550.
BT
#1009








                                      UNCLASSIFIED

[Top]


| First Page | Prev Page | Next Page | Back to Text |